Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease

American Journal of Neuroradiology

Volumn 24, Issue 2, 2003, Pages 234-238

  Barthel, Henryk ^a,c   Hermann, Wieland ^a   Kluge, Regine ^a   Hesse, Swen ^a   Collingridge, David R ^b   Wagner, Armin ^a   Sabri, Osama ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER I 123; COPPER; IODOBENZAMIDE I 123; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CALCULATION; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; FEMALE; HUMAN; MALE; MEDICAL DECISION MAKING; NEUROLOGIC DISEASE; NEUROTRANSMISSION; PARKINSONISM; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC NERVE; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WILSON DISEASE;

ADULT; BENZAMIDES; BRAIN MAPPING; CEREBELLUM; COCAINE; CORPUS STRIATUM; DOPAMINE; FEMALE; HEPATOLENTICULAR DEGENERATION; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PARKINSON DISEASE, SECONDARY; PSYCHOMETRICS; PYRROLIDINES; REFERENCE VALUES; SYNAPTIC TRANSMISSION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 20244377342     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Oder W, Prayer L, Grimm G, et al. Wilson's disease: evidence of subgroups derived from clinical findings and brain lesions. Neurology 1993;43:120-124
2. Barbosa ER, Caramelli P, Bacheschi LA, et al. Wilson's disease: magnetic resonance imaging (MRI) with clinical correlations in 16 cases. Rev Paul Med 1993;111(3):407-411
3. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with Parkinsonism. Eur J Nucl Med 1999;26:171-182
4. 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Commun 1991;12:699-707
5. Snow BJ, Bhatt M, Martin WR, Li D, Calne BD. The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography. J Neurol Neurosurg Psych 1991;54:12-17
6. Westermark K, Tedroff J, Thuomas KA, et al. Neurological Wilson's disease studies with magnetic resonance imaging and with positron emission tomography using dopaminergic markers. Mov Disord 1995;10:596-603
7. Schlaug G, Hefter H, Engelbrecht V, et al. Neurological impairment and recovery in Wilson's disease: evidence from PET and MRI. J Neurol Sci 1996;136:129-139
8. 123I-Iodobenzamide binding. J Neural Transm 1996;103:1093-1103
9. 123I]-β-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease. J Neurol Neurosurg Psych 1998;65:60-64
10. 64Cu. Clin Chem Acta 1972;42:353-359
11. Hermann W, Tietze F, Villmann T, Grahmann F, Wagner A. Clinical and fine motor therapy assessment in Wilson's disease. Nervenarzt 2000;71:970-974
12. 123I]β-CIT and high resolution SPECT. Eur J Nucl Med 2001;28:1656-1663
13. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with Iodine-123-β-CIT SPECT. J Nucl Med 1995;36:1175-1181
14. 123I-IBZM in humans. Ann Nucl Med 1993;7:29-38
15. Fletscher N. Movement disorders. In: Donaghy M, ed. Brain's Diseases of the Nervous System. Oxford: Oxford University Press; 2001:1015-1023
16. King AD, Walshe JM, Kendall BE, et al. Cranial MR imaging in Wilson's disease. AJR Am J Roentgenol 1996;167:1579-1584
17. Alanen A, Komu M, Penttinen M, Leino R. Magnetic resonance imaging and proton MR spectroscopy in Wilson's disease. Br J Radiol 1999;72:749-756
18. Magalhaes AC, Caramelli P, Menezes JR, et al. Wilson's disease: MRI with clinical correlation. Neuroradiology 1994;36:97-110
19. Weisner B, Hartard C, Dieu C. CSF copper concentration: a new parameter for diagnosis and monitoring therapy of Wilson's disease with cerebral manifestation. J Neurol Sci 1987;79:2290-2237
20. Kodama H, Okabe I, Yanagisawa M, et al. Does CSF copper level in Wilson disease reflect copper accumulation in the brain? Pediatr Neurol 1988;4:35-37
21. Barbeau A, Friesen H. Treatment of Wilson's disease with L-dopa after failure with penicillamine. Lancet 1970;1:1180-1181
22. Berio A, Vento R, Di Stefano A. Favorable results with an association of L-dopa and amantadine added to penicillamine in the treatment of Wilson's disease. Minerva Pediatr 1973;25:807-813
23. Gelmers HJ, Troost J, Willemse J. Wilson's disease: Modification by L-dopa. Neuropediatriatrics 1973;4:453-457
24. Frankel JP, Hughes A, Lees AJ, Stern GM, Walshe JM. Use of apomorphine to test for dopamine responsiveness in Wilson's disease. Lancet 1989;2:801-802
25. Morgan JP, Preziosi TJ, Bianchine JR. Ineffectiveness of L-dopa as supplement to penicillamine in a case of Wilson's disease. Lancet 1970;26:659
26. Wenning GK, Quinn NP. Parkinsonism: multiple system atrophy. Baillieres Clin Neurol 1997;6:187-204